These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3756626)

  • 1. Behavioral effect of cholecystokinin octapeptide in vagotomized rats.
    Itoh S; Katsuura G
    Can J Physiol Pharmacol; 1986 Jun; 64(6):745-7. PubMed ID: 3756626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking of cholecystokinin octapeptide behavioral effects by proglumide.
    Katsuura G; Hsiao S; Itoh S
    Peptides; 1984; 5(3):529-34. PubMed ID: 6089145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversed behavioral effect of cholecystokinin after frontal decortication in rats.
    Itoh S; Katsuura G; Itoh T; Morimoto T
    Life Sci; 1994; 55(11):PL213-6. PubMed ID: 8072383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of cholecystokinin and vasoactive intestinal peptide on locomotion and rearing in neofrontal decorticated rats.
    Katsuura G; Itoh S
    Prog Clin Biol Res; 1985; 192():147-50. PubMed ID: 4080707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cataleptogenic and anticataleptic activity produced by cholecystokinin octapeptides in mice.
    Kádár T; Borda L; Penke B; Kovács K; Telegdy G
    Neuropeptides; 1985 Jun; 6(3):259-68. PubMed ID: 4040614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bilateral subdiaphragmatic vagotomy does not prevent the behavioral effects of systematically administered ceruletide in mice.
    Moroji T; Hagino Y
    Neuropeptides; 1987 Apr; 9(3):217-24. PubMed ID: 3601011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Centrally administered CCK-8 suppresses activity in mice by a "peripheral-type" CCK receptor.
    Britton DR; Yahiro L; Cullen MJ; Kerwin JF; Kopecka H; Nadzan AM
    Pharmacol Biochem Behav; 1989 Dec; 34(4):779-83. PubMed ID: 2623030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abdominal vagal mediation of the satiety effects of exogenous and endogenous cholecystokinin in rats.
    Reidelberger RD
    Am J Physiol; 1992 Dec; 263(6 Pt 2):R1354-8. PubMed ID: 1481948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cholecystokinin on apomorphine-induced changes of motility in rats.
    Katsuura G; Itoh S; Rehfeld JF
    Neuropharmacology; 1984 Jul; 23(7A):731-4. PubMed ID: 6089021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A behavioural pharmacological study on intracerebroventricularly administered CCK-8 related peptides in mice.
    Hagino Y; Moroji T; Iizuka R
    Neuropeptides; 1989; 13(2):107-13. PubMed ID: 2739882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered responding to cholecystokinins and dopaminergic agonists following 6-hydroxydopamine treatment in rats.
    Hsiao S; Katsuura G; Itoh S
    Behav Neurosci; 1985 Oct; 99(5):853-60. PubMed ID: 3939625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral effects of cholecystokinin and its related peptides in rats.
    Itoh S; Katsuura G
    Prog Clin Biol Res; 1985; 192():139-45. PubMed ID: 2934743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of cholecystokinin on central monoaminergic pathways.
    Widerlöv E; Kalivas PW; Lewis MH; Prange AJ; Breese GR
    Regul Pept; 1983 May; 6(2):99-109. PubMed ID: 6308717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral evidence for cholecystokinin modulation of dopamine in the mesolimbic pathway.
    Crawley JH
    Prog Clin Biol Res; 1985; 192():131-8. PubMed ID: 4080706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specificity of nucleus accumbens to activities related to cholecystokinins in rats.
    Katsuura G; Itoh S; Hsiao S
    Peptides; 1985; 6(1):91-6. PubMed ID: 3991366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vagotomy does not alter cholecystokinin's inhibition of sham feeding.
    Kraly FS
    Am J Physiol; 1984 May; 246(5 Pt 2):R829-31. PubMed ID: 6326619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholecystokinin type A and type B receptor antagonists produce opposing effects on cholecystokinin-stimulated beta-endorphin secretion from the rat pituitary.
    Millington WR; Mueller GP; Lavigne GJ
    J Pharmacol Exp Ther; 1992 May; 261(2):454-61. PubMed ID: 1578360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholecystokinin intracerebroventricularly applied stimulates gastric acid secretion.
    Ishikawa T; Osumi Y; Nakagawa T
    Brain Res; 1985 Apr; 333(1):197-9. PubMed ID: 3995287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vagotomy does not affect thermal responsiveness to intrabrain prostaglandin E2 and cholecystokinin octapeptide.
    Sugimoto N; Simons CT; Romanovsky AA
    Brain Res; 1999 Oct; 844(1-2):157-63. PubMed ID: 10536272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholecystokinin-induced suppression of locomotion is attenuated in capsaicin pretreated rats.
    Ritter RC; Kalivas P; Bernier S
    Peptides; 1986; 7(4):587-90. PubMed ID: 3763436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.